-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »SEARCH RESULT
Drug makers suffer an overdose of control-Bhupesh Bhandari
-The Business Standard The new price caps for 191 essential drugs are likely to introduce serious distortions in the market for these medicines The National Pharmaceutical Pricing Authority, or NPPA, has announced new price caps for 191 essential drugs that are 10 to 50 per cent lower than the current prices. Drug makers have 45 days to recall the earlier batches and send out new ones with the lower price tags. This...
More »SMS, RTI potent tools of drug companies fighting patent battle -Soma Das
-The Economic Times NEW DELHI: As patent wars heat up in the pharma space, mobile phone messages and Right to Information filings have emerged as potent weapons in the hands of multinationals keen to delay competition from low-cost generic versions of their patented products in India. Innovator drugmakers, who used to strike with patent suits after generic drugmakers released their versions in the market, have started gleaning information from text messages sent...
More »Another bitter pill for patients-Sakthivel Selvaraj
-The Hindu The current market prices are essentially over and above the actual cost of production - a difference that could run from 100 per cent to 5,600 per cent, depending upon various therapeutic categories In a liberalised market economy, do we need price controls on drugs? Policymakers and the pharmaceutical industry do not think so. They believe that price controls are an inefficient tool that distorts resource allocation, squeezes revenue, reduces...
More »Paying the price-Ramya Kannan
-The Hindu The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...
More »